|
|
 |
|
|
 |
AMORCYTE, A NEOSTEM COMPANY, ENROLLS FIRST PATIENT IN PRESERVE PHASE 2 TRIAL FOR ACUTE MYOCARDIAL INFARCTION
New York, NY (January 25, 2012)
SENIOR MANAGEMENT OF NEOSTEM AND ITS SUBSIDIARIES INVITED TO SPEAK AT SEVENTH INTERNATIONAL CONFERENCE ON CELL THERAPY FOR CARDIOVASCULAR DISEASE
New York, NY January 23, 2012)
AMORCYTE, A NEOSTEM COMPANY, ANNOUNCES EXPANSION OF INTELLECTUAL PROPERTY
New York, NY (January 10, 2012)
NEOSTEM ACQUIRES AMORCYTE, A CLINICAL STAGE CARDIOVASCULAR DISEASE CELL THERAPY COMPANY
New York, NY (October 17, 2011)
NEOSTEM PROVIDES UPDATE ON AMORCYTE CLINICAL PROGRESS AND REPORTS RESULTS FOR SECOND QUARTER
New York, NY (August 15, 2011)
NEOSTEM SIGNS DEFINITIVE MERGER AGREEMENT TO ACQUIRE AMORCYTE IN EQUITY TRANSACTION
New York, NY (July 14, 2011)
AMORCYTE REPORTS PHASE I RESULTS OF AMR-001 TO IMPROVE RECOVERY FROM SEVERE HEART ATTACK AT ACC ANNUAL SCIENTIFIC SESSION
First Stem Cell Trial to Show Dose-related Significant Improvement in Perfusion
Orlando, Fla, (March 30, 2009)
After Heart Attack, Bone Marrow Stem Cells Increase Blood Flow Within Heart
Orlando, Fla, (March 30, 2009)
AMORCYTE COMPLETES PHASE I TRIAL OF STEM CELL THERAPY FOR ACUTE MYOCARDIAL INFARCTION
(Amorcyte) announced today the completion of the phase I clinical trial of its lead product, AMR-001.
HACKENSACK, New Jersey - (April 1, 2008)
AMORCYTE CARDIAC CELL THERAPY TRIAL COMPLETES SECOND OF FOUR PHASES
Stem cell therapy trial picks up pace with three sites now accruing patients
HACKENSACK, New Jersey - (May 8, 2007)
PAUL HARVEY, CELEBRATED NEWS COMMENTATOR, DISCUSSED THE AMORCYTE-FUNDED STUDY IN HIS FRIDAY MORNING BROADCAST
Referring to the study as “rescuing heart attack victims by regenerating heart muscle with stem cell therapy”.
HACKENSACK, New Jersey - (April 13, 2007)
AMORCYTE CARDIAC CELL THERAPY TRIAL PASSES FIRST STAGE AND OPENS TWO NEW SITES
Stem cell therapy trial proceeds to next stage and opens in two new clinical centers
HACKENSACK, New Jersey - (January 2, 2007)
AMORCYTE SECURES ADDITIONAL FUNDING TO EXPAND CLINICAL PROGRAM IN CARDIOVASCULAR THERAPY
PA Early Stage joins Colt Ventures in expanding Amorcyte’s product program
Hackensack, New Jersey (PRWEB) October 23, 2006
AMORCYTE SECURES PRODUCTION CAPACITY FOR LEAD CELL THERAPY PRODUCT
Progenitor Cell Therapy LLC is retained to develop and manufacture AMR-001.
Hackensack, NJ (PRWEB) June 28, 2006
AMORCYTE CLOSES $4.2 MILLION SERIES A FINANCING
Financing to fund 40-patient cardiovascular cell therapy trial
HACKENSACK, New Jersey - (June 19, 2006)
AMORCYTE, INC OPENS CELL THERAPY TRIAL FOR CARDIOVASCULAR DISEASE AT EMORY UNIVERSITY
Initial Study to Focus on Safety, Efficacy, and Mechanism of Action
HACKENSACK, New Jersey - (June 5, 2006)
|
|
|
